An Exceptional Responder to Nivolumab in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Literature Review of Long-Term Survivors

<div>PET/CT images showing increased metabolic activity in the mediastinum (a) and in the liver (b) prior to initiating nivolumab. Resolution of FDG-avid lesions in the mediastinum (c) and in the liver (d) 10 months after discontinuation of nivolumab.</div>

Case Reports in Oncological Medicine

fig2

Figure 2

Figure 2: An Exceptional Responder to Nivolumab in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Literature Review of Long-Term Survivors 